{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:40:24Z","timestamp":1793133624190,"version":"4.5.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)\u2013modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes of outpatient administration of all commercially available CD19- and B-cell maturation antigen (BCMA)\u2013directed CAR T-cell therapy using a strategy of no remote at-home monitoring and an early cytokine release syndrome (CRS) intervention strategy. Patients with hematologic malignancies who received CAR T-cell therapy in the outpatient setting during 2022 to 2023 were included. Patients were seen daily in the cancer center day hospital for the first 7 to 10\u00a0days and then twice weekly through day 30. The primary end point was to determine 3-, 7-, and 30-day post\u2013CAR T-cell infusion hospitalizations. Early CRS intervention involved administering tocilizumab as an outpatient for grade \u22651 CRS. Fifty-eight patients received outpatient CAR T-cell infusion (33 myeloma, 24 lymphoma, and 1 acute lymphoblastic leukemia). Of these, 17 (41%), 16 (38%), and 9 patients (21%) were admitted between days 0 to 3, 4 to 7, and 8 to 30 after CAR T-cell infusion, respectively. The most common reason for admission was CAR T-cell\u2013related toxicities (33\/42). Hospitalization was prevented in 15 of 35 patients who received tocilizumab for CRS as an outpatient. The nonrelapse mortality rates were 1.7% at 1\u00a0month and 3.4% at 6\u00a0months. In conclusion, we demonstrate that the administration of commercial CAR T-cell therapies in an outpatient setting is safe and feasible without intensive remote monitoring using an early CRS intervention strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013239","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T16:53:57Z","timestamp":1718729637000},"page":"4320-4329","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7262-4953","authenticated-orcid":false,"given":"Fateeha","family":"Furqan","sequence":"first","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineel","family":"Bhatlapenumarthi","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4377-9742","authenticated-orcid":false,"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqa","family":"Farrukh","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Jefferson Abington Hospital, Abington, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Longo","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Akhtar","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo","family":"Pasquini","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru Subramanian","family":"Guru Murthy","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Runaas","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-6526","authenticated-orcid":false,"given":"Meera","family":"Mohan","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[{"name":"1Blood and Marrow Transplant and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"issue":"26","key":"2024082713011462300_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2024082713011462300_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024082713011462300_bib3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024082713011462300_bib4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","article-title":"Updated indications for immune effector cell therapy: 2023 guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10297","key":"2024082713011462300_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"2024082713011462300_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"2024082713011462300_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024082713011462300_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024082713011462300_bib9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024082713011462300_bib10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10343","key":"2024082713011462300_bib11","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"2024082713011462300_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"43","key":"2024082713011462300_bib13","doi-asserted-by":"crossref","first-page":"e397912","DOI":"10.1200\/EDBK_397912","article-title":"High cost of chimeric antigen receptor T-cells: challenges and solutions","volume":"43","author":"Cliff","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"2024082713011462300_bib14","doi-asserted-by":"crossref","first-page":"e202072","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2024082713011462300_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/hex.12619","article-title":"Impact and experiences of delayed discharge: a mixed-studies systematic review","volume":"21","author":"Rojas-Garcia","year":"2018","journal-title":"Health Expect"},{"issue":"3","key":"2024082713011462300_bib16","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2019.12.093","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) in 3 ongoing clinical studies in relapsed\/refractory (R\/R) large B cell non-Hodgkin lymphoma (NHL), including second-line transplant noneligible (TNE) patients: Transcend NHL 001, Outreach, and PILOT","volume":"26","author":"Bachier","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2024082713011462300_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41409-022-01664-z","article-title":"Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center","volume":"57","author":"Borogovac","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2024082713011462300_bib18","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"2024082713011462300_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jtct.2022.06.021","article-title":"Real-world experience and optimization of outpatient chimeric antigen receptor T cell therapy","volume":"28","author":"McGann","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2024082713011462300_bib20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.7812\/TPP\/23.022","article-title":"Benefits and challenges of remote patient monitoring as perceived by health care practitioners: a systematic review","volume":"27","author":"Serrano","year":"2023","journal-title":"Perm J"},{"issue":"4","key":"2024082713011462300_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024082713011462300_bib22","doi-asserted-by":"crossref","first-page":"449.e1","DOI":"10.1016\/j.jtct.2023.04.019","article-title":"Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma","volume":"29","author":"Ahmed","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"suppl 15","key":"2024082713011462300_bib23","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"38","author":"Bachier","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"2024082713011462300_bib24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jtct.2023.11.008","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2024082713011462300_bib25","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jtct.2021.01.014","article-title":"Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration","volume":"27","author":"Alexander","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"24","key":"2024082713011462300_bib26","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2024082713011462300_bib27","doi-asserted-by":"crossref","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2024082713011462300_bib28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bmt.2015.46","article-title":"Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma","volume":"50","author":"Graff","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024082713011462300_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.bbmt.2018.12.069","article-title":"Outcomes of reduced-intensity conditioning allogeneic hematopoietic cell transplantation performed in the inpatient versus outpatient setting","volume":"25","author":"Guru Murthy","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16 suppl","key":"2024082713011462300_bib30","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1200\/JCO.2023.41.16_suppl.1533","article-title":"Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma","volume":"41","author":"Bansal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"2024082713011462300_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.amjcard.2021.03.023","article-title":"Patient and provider perspectives on remote monitoring of pacemakers and implantable cardioverter-defibrillators","volume":"149","author":"Fraiche","year":"2021","journal-title":"Am J Cardiol"},{"issue":"1","key":"2024082713011462300_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13741-020-00166-0","article-title":"Can technology optimise the pre-operative pathway for elective hip and knee replacement surgery: a qualitative study","volume":"9","author":"Sharif","year":"2020","journal-title":"Perioper Med (Lond)"},{"key":"2024082713011462300_bib33","author":"Shah","year":"28  2019"},{"issue":"suppl 1","key":"2024082713011462300_bib34","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2023-189349","article-title":"Comparison of bendamustine versus fludarabine\/ cyclophosphamide lymphodepletion in adult patients receiving CD19 CAR-T cell therapy","volume":"142","author":"Landego","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2024082713011462300_bib35","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/ajh.27069","article-title":"Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma","volume":"98","author":"Ong","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2024082713011462300_bib36","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.annonc.2022.05.521","article-title":"Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas","volume":"33","author":"Ghilardi","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"2024082713011462300_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2024082713011462300_bib38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4320\/2239746\/blooda_adv-2024-013239-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4320\/2239746\/blooda_adv-2024-013239-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:01:58Z","timestamp":1724749318000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4320\/516586\/Outpatient-administration-of-CAR-T-cell-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013239","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]}}}